4 completed, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow apraglutide: new trials by email Literature Review of apraglutide trials Research Report on apraglutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation Apraglutide - Healthy Subjects | Phase 1 | Completed | VectivBio AG | 34 | 2023-05-23 | 2024-10-26 |
| Evaluation of Apraglutide on Gastric Emptying Apraglutide, Placebo, Acetaminophen - Healthy Subjects | Phase 1 | Completed | VectivBio AG | 42 | 2023-03-02 | 2024-10-24 |
| A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function Apraglutide - Hepatic Impairment | Phase 1 | Completed | VectivBio AG | 16 | 2023-01-30 | 2025-07-10 |
| Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function. Apraglutide - Chronic Kidney Disease | Phase 1 | Completed | VectivBio AG | 16 | 2020-12-08 | 2024-10-26 |
| Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas FE 203799 - Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult | Phase 1 / Phase 2 | Withdrawn | GlyPharma Therapeutics | 2018-09-01 | 2024-10-24 |
Hodgkin Disease (1) · Lymphoma (1) · Mucositis (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
VectivBio AG (4) · GlyPharma Therapeutics (1)
Netherlands (2) · Germany (1) · Slovakia (1) · United States (1)
Tomasz Masior (5)